Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.
Paola CircostaChiara DoniniSusanna GalloLidia GiraudoLoretta GammaitoniRamona RotoloFederica GalvagnoSonia CapelleroMarco BasiricòMonica CasucciMassimo AgliettaIvana FerreroFranca FagioliAlessandro CignettiFabrizio Carnevale-SchiancaValeria LeuciDario SangioloPublished in: British journal of haematology (2022)
Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- bone marrow
- stem cell transplantation
- cell therapy
- endothelial cells
- peritoneal dialysis
- rheumatoid arthritis
- stem cells
- low dose
- mesenchymal stem cells
- oxidative stress
- peripheral blood
- risk assessment
- high dose
- cell death
- ulcerative colitis
- cell cycle arrest
- disease activity